A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
August 7, 2019
Primary Completion Date
December 11, 2019
Study Completion Date
December 11, 2019
Conditions
Safety
Interventions
BIOLOGICAL
PRV-3279 or placebo
bi-specific antibody-based molecule
Trial Locations (1)
21225
Clinical site, Baltimore
All Listed Sponsors
lead
Provention Bio, Inc.
INDUSTRY
NCT03955666 - A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects | Biotech Hunter | Biotech Hunter